CureVac N.V.
NASDAQ:CVAC 4:00:00 PM EDT
Products
Curevac: Positive Data In Older Adults From Covid-19, Flu MRNA Vaccine Development Programs
Published: 01/30/2023 12:11 GMT
CureVac N.V. (CVAC) - Eqs-news: Curevac Announces Positive Data in Older Adults From Covid-19 and Flu Mrna Vaccine Development Programs.
Continued Technology Platform Validation With Extended Preliminary Data From Older Adults in Ongoing Phase 1 Studies in Covid-19 and Flu.
Covid-19: Monovalent Modified Mrna Construct Cv0501 Successfully Boosted Antibody Titers Against Ba.
1 and Ancestral Variants in Adults Age ≥65.
Flu: Monovalent Modified Mrna Construct Flu-sv-mrna Elicited Antibodies Approximately 2.3 Times Those of Licensed Vaccine Comparator in Adults Aged 60-80.
Reaffirming Plan to Advance Modified Mrna Covid-19 and Flu Candidates to Next Stages of Clinical Development in Collaboration With Gsk in 2023.
Further Company Coverage: .
(reporting by Berlin Newsroom).
((berlin.
Newsroom@thomsonreuters.
Com;)).
Continued Technology Platform Validation With Extended Preliminary Data From Older Adults in Ongoing Phase 1 Studies in Covid-19 and Flu.
Covid-19: Monovalent Modified Mrna Construct Cv0501 Successfully Boosted Antibody Titers Against Ba.
1 and Ancestral Variants in Adults Age ≥65.
Flu: Monovalent Modified Mrna Construct Flu-sv-mrna Elicited Antibodies Approximately 2.3 Times Those of Licensed Vaccine Comparator in Adults Aged 60-80.
Reaffirming Plan to Advance Modified Mrna Covid-19 and Flu Candidates to Next Stages of Clinical Development in Collaboration With Gsk in 2023.
Further Company Coverage: .
(reporting by Berlin Newsroom).
((berlin.
Newsroom@thomsonreuters.
Com;)).